Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Klein, Matthias S ^a   Shearer, Jane ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYBUTYRIC ACID; AMINO ACID DERIVATIVE; AROMATIC AMINO ACID; BRANCHED CHAIN AMINO ACID; GLYCINE; LYSOPHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

AMINO ACID BLOOD LEVEL; BASIC RESEARCH; DISEASE MARKER; HUMAN; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; REVIEW; BLOOD; PROCEDURES; TRANSLATIONAL RESEARCH;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLOMICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84948456339     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/3898502     Document Type: Review

References (75)

1. S. Smyth and A. Heron, "Diabetes and obesity: the twin epidemics," Nature Medicine, vol. 12, no. 1, pp. 75-80, 2006.
2. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, "Idf diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030," Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311-321, 2011.
3. J. Lindström and J. Tuomilehto, "The diabetes risk score: a practical tool to predict type 2 diabetes risk," Diabetes Care, vol. 26, no. 3, pp. 725-731, 2003.
4. A. P. Carson, K. Reynolds, V. A. Fonseca, and P. Muntner, "Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults," Diabetes Care, vol. 33, no. 1, pp. 95-97, 2010.
5. X.-R. Pan, G.-W. Li, Y.-H. Hu et al., "Effects of diet and exercise in preventing NIDDMin people with impaired glucose tolerance: the Da Qing IGT and diabetes study," Diabetes Care, vol. 20, no. 4, pp. 537-544, 1997.
6. J. Tuomilehto, J. Lindström, J. G. Eriksson et al., "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance," The New England Journal of Medicine, vol. 344, no. 18, pp. 1343-1350, 2001.
7. W. C. Knowler, E. Barrett-Connor, S.E. Fowler et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," The New England Journal of Medicine, vol. 346, no. 6, pp. 393-403, 2002.
8. H. C. Gerstein, S. Yusuf, J. Bosch et al., "Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial," The Lancet, vol. 368, no. 9541, pp. 1096-1105, 2006.
9. S. M. Grundy, C. E. Barlow, S. W. Farrell, G. L. Vega, and W. L. Haskell, "Cardiorespiratory fitness and metabolic risk," American Journal of Cardiology, vol. 109, no. 7, pp. 988-993, 2012.
10. J. L. Rosenzweig, E. Ferrannini, S. M. Grundy et al., "Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline," The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 10, pp. 3671-3689, 2008.
11. J. Liu, S. M. Grundy, W. Wang et al., "Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome," The American Heart Journal, vol. 153, no. 4, pp. 552-558, 2007.
12. S. B. Heymsfield, D. Thomas, A. Bosy-Westphal, W. Shen, C. M. Peterson, and M. J. Müller, "Evolving concepts on adjusting human resting energy expenditure measurements for body size," Obesity Reviews, vol. 13, no. 11, pp. 1001-1014, 2012.
13. M. J. Müller, M. Lagerpusch, J. Enderle, B. Schautz, M. Heller, and A. Bosy-Westphal, "Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome," Obesity Reviews, vol. 13, no. 2, pp. 6-13, 2012.
14. D. M. Mutch, M. R. Temanni, C. Henegar et al., "Adipose gene expression prior to weight loss can differentiate and weakly predict dietary responders," PLoS ONE, vol. 2, no. 12, Article ID e1344, 2007.
15. H. U. Zacharias, J. Hochrein, M. S. Klein, C. Samol, P. Oefner, and W. Gronwald, "Current experimental, bioinformatic and statistical methods used in nmr based metabolomics," Current Metabolomics, vol. 1, no. 3, pp. 253-268, 2013.
16. J. C. Lindon and J. K. Nicholson, "Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics," Annual Review of Analytical Chemistry, vol. 1, no. 1, pp. 45-69, 2008.
17. R. Ramautar, G. W. Somsen, and G. J. de Jong, "CE-MS for metabolomics: developments and applications in the period 2010-2012," Electrophoresis, vol. 34, no. 1, pp. 86-98, 2013.
18. K. Kubota, T. Fukushima, R. Yuji et al., "Development of an HPLC-fluorescence determinationmethod for carboxylic acids related to the tricarboxylic acid cycle as a metabolome tool," Biomedical Chromatography, vol. 19, no. 10, pp. 788-795, 2005.
19. W. Gronwald, M. S. Klein, H. Kaspar et al., "Urinary metabolite quantification employing 2D NMR spectroscopy," Analytical Chemistry, vol. 80, no. 23, pp. 9288-9297, 2008.
20. M. S. Klein, P. J. Oefner, and W. Gronwald, "Metaboquant: a tool combining individual peak calibration and outlier detection for accuratemetabolite quantification in 1d 1h and 1h-13c hsqc nmr spectra," BioTechniques, vol. 54, no. 5, pp. 251-256, 2013.
21. M. S. Klein, K. E. Connors, J. Shearer, H. J. Vogel, and D. S. Hittel, "Metabolomics reveals the sex-specific effects of the sort1 low-density lipoprotein cholesterol locus in healthy young adults," Journal of Proteome Research, vol. 13, no. 11, pp. 5063-5070, 2014.
22. H.U. Zacharias, G. Schley, J. Hochrein et al., "Analysis of human urine reveals metabolic changes related to the development of acute kidney injury following cardiac surgery," Metabolomics, vol. 9, no. 3, pp. 697-707, 2013.
23. A.-H. Zhang, H. Sun, G.-L. Yan, Y. Yuan, Y. Han, and X.-J. Wang, "Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods," Journal of Physiology and Biochemistry, vol. 70, no. 1, pp. 117-128, 2014.
24. E. Trushina, T. Dutta, X.-M. T. Persson, M. M. Mielke, and R. C. Petersen, "Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics," PLoS ONE, vol. 8, no. 5, Article ID e63644, 2013.
25. D.O. Mook-Kanamori, M. M. E.-D. Selim, A. H. Takiddin, A. H. Takiddin et al., "1, 5-anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control," The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. E479-E483, 2014.
26. W. Römisch-Margl, C. Prehn, R. Bogumil, C. Röhring, K. Suhre, and J. Adamski, "Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics," Metabolomics, vol. 8, no. 1, pp. 133-142, 2012.
27. O. Beckonert, M. Coen, H. C. Keun et al., "High-resolution magic-angle-spinning NMR spectroscopy for metabolic profilingof intact tissues," Nature protocols, vol. 5, no.6, pp. 1019-1032, 2010.
28. H. M. de Feyter, G. F. Mason, G. I. Shulman, D. L. Rothman, and K. F. Petersen, "Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals," Diabetes, vol. 62, no. 9, pp. 3075-3080, 2013.
29. M. Wallace, H. Whelan, and L. Brennan, "Metabolomic analysis of pancreatic beta cells following exposure to high glucose," Biochimica et Biophysica Acta, vol. 1830, no. 3, pp. 2583-2590, 2013.
30. Z. Yu, G. Kastenmüller, Y. He et al., "Differences between human plasma and serum metabolite profiles," PLoS ONE, vol. 6, no. 7, Article ID e21230, 2011.
31. D. G. A. J. Hebels, P. Georgiadis, H. C. Keun et al., "Performance in omics analyses of blood samples in long-term storage: opportunities for the exploitation of existing biobanks in environmental health research," Environmental Health Perspectives, vol. 121, no. 4, pp. 480-487, 2013.
32. W. B. Dunn, D. Broadhurst, D. I. Ellis et al., "A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols," International Journal of Epidemiology, vol. 37, supplement 1, pp. i23-i30, 2008.
33. H. G. Gika, G. A. Theodoridis, and I. D. Wilson, "Liquid chromatography and ultra-performance liquid chromatographymass spectrometry fingerprinting of human urine. Sample stability under different handling and storage conditions for metabonomics studies," Journal of Chromatography A, vol. 1189, no. 1-2, pp. 314-322, 2008.
34. T. J. Wang, D. Ngo, N. Psychogios et al., "2-Aminoadipic acid is a biomarker for diabetes risk," The Journal of Clinical Investigation, vol. 123, no. 10, pp. 4309-4317, 2013.
35. G.A. Walford, B.C. Porneala, M. Dauriz et al., "Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes," Diabetes Care, vol. 37, no. 9, pp. 2508-2514, 2014.
36. A. Floegel, N. Stefan, Z. Yu et al., "Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach," Diabetes, vol. 62, no. 2, pp. 639-648, 2013.
37. R. Wang-Sattler, Z. Yu, C. Herder et al., "Novel biomarkers for pre-diabetes identified bymetabolomics," Molecular Systems Biology, vol. 8, article 615, 2012.
38. M. S. Lustgarten, L. Lyn Price, E. M. Phillips, and R. A. Fielding, "Serum glycine is associated with regional body fat and insulin resistance in functionally-limited older adults," PLoS ONE, vol. 8, no. 12, Article ID e84034, 2013.
39. P. Würtz, V.-P. Mäkinen, P. Soininen et al., "Metabolic signatures of insulin resistance in 7,098 young adults," Diabetes, vol. 61, no. 6, pp. 1372-1380, 2012.
40. T. J. Wang, M. G. Larson, R. S. Vasan et al., "Metabolite profiles and the risk of developing diabetes," Nature Medicine, vol. 17, no. 4, pp. 448-453, 2011.
41. I. Padberg, E. Peter, S. González-Maldonado et al., "A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology," PLoS ONE, vol. 9, no. 1, Article ID e85082, 2014.
42. E. Ferrannini, A. Natali, S. Camastra et al., "Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance," Diabetes, vol. 62, no. 5, pp. 1730-1737, 2013.
43. C. Menni, E. Fauman, I. Erte et al., "Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach," Diabetes, vol. 62, no. 12, pp. 4270-4276, 2013.
44. C. B. Newgard, J. An, J. R. Bain et al., "A branched-chain amino acid-relatedmetabolic signature that differentiates obese and lean humans and contributes to insulin resistance," Cell Metabolism, vol. 9, no. 4, pp. 311-326, 2009.
45. D. Newbern, P. Gumus Balikcioglu, M. Balikcioglu et al., "Sex differences in biomarkers associated with insulin resistance in obese adolescents: metabolomic profiling and principal components analysis," The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 12, pp. 4730-4739, 2014.
46. F. Xu, S. Tavintharan, C. F. Sum, K. Woon, S. C. Lim, and C. N. Ong, "Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics," Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. E1060-E1065, 2013.
47. J. Cobb, A. Eckhart, R. Perichon et al., "A novel test for IGT utilizing metabolite markers of glucose tolerance," Journal of Diabetes Science and Technology, vol. 9, no. 1, pp. 69-76, 2014.
48. W. E. Gall, K. Beebe, K. A. Lawton et al., "α-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population," PLoS ONE, vol. 5, no. 5, Article ID e10883, 2010.
49. K. Suhre, C. Meisinger, A. Döring et al., "Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting," PLoS ONE, vol. 5, no. 11, Article ID e13953, 2010.
50. P. Kaur, N. Rizk, S. Ibrahim et al., "Quantitative metabolomic and lipidomic profiling reveals aberrant amino acidmetabolism in type 2 diabetes," Molecular BioSystems, vol. 9, no. 2, pp. 307-317, 2013.
51. C. Langenberg and D. B. Savage, "An amino acid profile to predict diabetes?" Nature Medicine, vol. 17, no. 4, pp. 418-420, 2011.
52. B. C. Batch, K. Hyland, and L. P. Svetkey, "Branch chain amino acids: biomarkers of health and disease," Current Opinion in Clinical Nutrition & Metabolic Care, vol. 17, no. 1, pp. 86-89, 2014.
53. M. Monirujjaman and A. Ferdouse, "Metabolic and physiological roles of branched-chain amino acids," Advances in Molecular Biology, vol. 2014, Article ID 364976, 6 pages, 2014.
54. R. V. Sekhar, S. V. Mckay, S. G. Patel et al., "Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine," Diabetes Care, vol. 34, no. 1, pp. 162-167, 2011.
55. T. R. Koves, J. R. Ussher, R. C. Noland et al., "Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance," Cell Metabolism, vol. 7, no. 1, pp. 45-56, 2008.
56. K. Morino, K. F. Petersen, and G. I. Shulman, "Molecularmechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction," Diabetes, vol. 55, supplement 2, pp. S9-S15, 2006.
57. T. O'Brien, T. T. Nguyen, and B. R. Zimmerman, "Hyperlipidemia and diabetes mellitus," Mayo Clinic Proceedings, vol. 73, no. 10, pp. 969-976, 1998.
58. T. Soga, T. Ohishi, T. Matsui et al., "Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan Gprotein-coupled receptor," Biochemical and Biophysical Research Communications, vol. 326, no. 4, pp. 744-751, 2005.
59. M. B. Schulze, K. Hoffmann, H. Boeing et al., "An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes," Diabetes Care, vol. 30, no. 3, pp. 510-515, 2007.
60. J. L. Vassy, M.-F. Hivert, B. Porneala et al., "Polygenic type 2 diabetes prediction at the limit of common variant detection," Diabetes, vol. 63, no. 6, pp. 2172-2182, 2014.
61. M. J. Pencina, R. B. D'Agostino, R. B. D'Agostino Jr., and R. S. Vasan, "Evaluating the added predictive ability of a newmarker: fromarea under the ROC curve to reclassification and beyond," Statistics in Medicine, vol. 27, no. 2, pp. 157-172, 2008.
62. N. Sarwar, P. Gao, S. R. Seshasai et al., "Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies," The Lancet, vol. 375, pp. 2215-2222, 2010.
63. S. H. Saydah, J. Fradkin, and C. C. Cowie, "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes," The Journal of the American Medical Association, vol. 291, no. 3, pp. 335-342, 2004.
64. T. Wu, G. Xie, Y. Ni et al., "Serummetabolite signatures of type 2 diabetes mellitus complications," Journal of Proteome Research, vol. 14, no. 1, pp. 447-456, 2015.
65. R. Roussel, F. Mentré, N. Bouchemal et al., "NMR-based prediction of cardiovascular risk in diabetes," Nature Medicine, vol. 13, no. 4, pp. 399-400, 2007.
66. K. Sharma, B. Karl, A. V. Mathew et al., "Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease," Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1901-1912, 2013.
67. M. A. Niewczas, T. L. Sirich, A. V. Mathew et al., "Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study," Kidney International, vol. 85, no. 5, pp. 1214-1224, 2014.
68. M. Huang, Q. Liang, P. Li et al., "Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system," Molecular BioSystems, vol. 9, no. 8, pp. 2134-2141, 2013.
69. C. Hernández and R. Simó, "Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice," Expert Opinion on Investigational Drugs, vol. 16, no. 8, pp. 1209-1226, 2007.
70. I. Barba, M. Garcia-Ramírez, C. Hernández et al., "Metabolic fingerprints of proliferative diabetic retinopathy: an 1H-NMRbasedmetabonomic approach using vitreous humor," Investigative Ophthalmology and Visual Science, vol. 51, no. 9, pp. 4416-4421, 2010.
71. S. A. Varvel, S. Voros, D. L. Thiselton et al., "Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and hba1c and is associated with improved glycemic control in clinical practice," Journal of Cardiovascular Translational Research, vol. 7, no. 6, pp. 597-606, 2014.
72. M. Assfalg, I. Bertini, D. Colangiuli et al., "Evidence of different metabolic phenotypes in humans," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1420-1424, 2008.
73. C. Gieger, L. Geistlinger, E. Altmaier et al., "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum," PLoS Genetics, vol. 4, no. 11, Article ID e1000282, 2008.
74. T. Illig, C. Gieger, G. Zhai et al., "A genome-wide perspective of genetic variation in human metabolism," Nature Genetics, vol. 42, no. 2, pp. 137-141, 2010.
75. G. Nicholson, M. Rantalainen, J. V. Li et al., "A genomewide metabolic QTL analysis in europeans implicates two Loci shaped by recent positive selection," PLoS Genetics, vol. 7, no. 9, Article ID e1002270, 2011.